Full year results for the year ended 31 December 2020 reflect a period of change for the company as it sets the stage for the commercialisation of its next-generation DNA synthesis and delivery technology. 4basebio UK Societas was spun out of 4basebio AG (now 2Invest AG) on 8 December 2020, and was admitted to AIM on 17 February 2021. 4basebio generated revenues of £0.46m (2019: £0.20m, +129%), with a pre-tax loss of £0.72m (2019: £0.53m, +35%), with year-end cash of £15.0m (versus our £14.6m es ....
04 Jun 2021
4basebio - FY2020: setting the stage for next-generation technology
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
4basebio - FY2020: setting the stage for next-generation technology
4basebio PLC (4BB:LON) | 1,045 0 0.0% | Mkt Cap: 133.8m
- Published:
04 Jun 2021 -
Author:
Mark Brewer | Cavendish Research -
Pages:
11
Full year results for the year ended 31 December 2020 reflect a period of change for the company as it sets the stage for the commercialisation of its next-generation DNA synthesis and delivery technology. 4basebio UK Societas was spun out of 4basebio AG (now 2Invest AG) on 8 December 2020, and was admitted to AIM on 17 February 2021. 4basebio generated revenues of £0.46m (2019: £0.20m, +129%), with a pre-tax loss of £0.72m (2019: £0.53m, +35%), with year-end cash of £15.0m (versus our £14.6m es ....